Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
about
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesEconomic evaluation of chronic lymphocytic leukemia from a hospital management perspective.Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.
P2860
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cost-effectiveness of rituxima ...... chronic lymphocytic leukemia.
@en
type
label
Cost-effectiveness of rituxima ...... chronic lymphocytic leukemia.
@en
prefLabel
Cost-effectiveness of rituxima ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P50
P1433
P1476
Cost-effectiveness of rituxima ...... chronic lymphocytic leukemia.
@en
P2093
Alexander Mensch
Daniele Civello
Dirk Müller
Günter Fingerle-Rowson
Jasmin Bahlo
Kirsten Fischer
Lenka Kellermann
Lisa Borsi
Marcel Reiser
Peter Kaiser
P2860
P304
P356
10.3109/10428194.2015.1070151
P577
2015-11-20T00:00:00Z